BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 20354120)

  • 1. Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a 68Ga- and 18F-labeled hapten peptide in mice with human tumor xenografts.
    Schoffelen R; Sharkey RM; Goldenberg DM; Franssen G; McBride WJ; Rossi EA; Chang CH; Laverman P; Disselhorst JA; Eek A; van der Graaf WT; Oyen WJ; Boerman OC
    Mol Cancer Ther; 2010 Apr; 9(4):1019-27. PubMed ID: 20354120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide.
    McBride WJ; Zanzonico P; Sharkey RM; Norén C; Karacay H; Rossi EA; Losman MJ; Brard PY; Chang CH; Larson SM; Goldenberg DM
    J Nucl Med; 2006 Oct; 47(10):1678-88. PubMed ID: 17015905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretargeted immunoPET of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody in mice with PC3 xenografts.
    van Rij CM; Frielink C; Goldenberg DM; Sharkey RM; Franssen GM; Lütje S; McBride WJ; Oyen WJ; Boerman OC
    Mol Imaging Biol; 2015 Feb; 17(1):94-101. PubMed ID: 25060065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promising clinical performance of pretargeted immuno-PET with anti-CEA bispecific antibody and gallium-68-labelled IMP-288 peptide for imaging colorectal cancer metastases: a pilot study.
    Touchefeu Y; Bailly C; Frampas E; Eugène T; Rousseau C; Bourgeois M; Bossard C; Faivre-Chauvet A; Rauscher A; Masson D; David A; Cerato E; Carlier T; Sharkey RM; Goldenberg DM; Barbet J; Kraeber-Bodere F; Bodet-Milin C
    Eur J Nucl Med Mol Imaging; 2021 Mar; 48(3):874-882. PubMed ID: 32820369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reagents and methods for PET using bispecific antibody pretargeting and 68Ga-radiolabeled bivalent hapten-peptide-chelate conjugates.
    Griffiths GL; Chang CH; McBride WJ; Rossi EA; Sheerin A; Tejada GR; Karacay H; Sharkey RM; Horak ID; Hansen HJ; Goldenberg DM
    J Nucl Med; 2004 Jan; 45(1):30-9. PubMed ID: 14734668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretargeted immuno-PET of CEA-expressing intraperitoneal human colonic tumor xenografts: a new sensitive detection method.
    Schoffelen R; van der Graaf WT; Sharkey RM; Franssen GM; McBride WJ; Chang CH; Laverman P; Goldenberg DM; Oyen WJ; Boerman OC
    EJNMMI Res; 2012 Jan; 2():5. PubMed ID: 22284761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and 68Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial.
    Bodet-Milin C; Faivre-Chauvet A; Carlier T; Rauscher A; Bourgeois M; Cerato E; Rohmer V; Couturier O; Drui D; Goldenberg DM; Sharkey RM; Barbet J; Kraeber-Bodere F
    J Nucl Med; 2016 Oct; 57(10):1505-1511. PubMed ID: 27230928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody.
    van Rij CM; Lütje S; Frielink C; Sharkey RM; Goldenberg DM; Franssen GM; McBride WJ; Rossi EA; Oyen WJ; Boerman OC
    Eur J Nucl Med Mol Imaging; 2013 Sep; 40(9):1377-83. PubMed ID: 23674207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody's valency for the tumor target antigen.
    Karacay H; Sharkey RM; McBride WJ; Griffiths GL; Qu Z; Chang K; Hansen HJ; Goldenberg DM
    Bioconjug Chem; 2002; 13(5):1054-70. PubMed ID: 12236788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immuno-PET of colorectal cancer with a CEA-targeted [68 Ga]Ga-nanobody: from bench to bedside.
    Li L; Lin X; Wang L; Ma X; Zeng Z; Liu F; Jia B; Zhu H; Wu A; Yang Z
    Eur J Nucl Med Mol Imaging; 2023 Oct; 50(12):3735-3749. PubMed ID: 37382662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metastatic human colonic carcinoma: molecular imaging with pretargeted SPECT and PET in a mouse model.
    Sharkey RM; Karacay H; Vallabhajosula S; McBride WJ; Rossi EA; Chang CH; Goldsmith SJ; Goldenberg DM
    Radiology; 2008 Feb; 246(2):497-507. PubMed ID: 18227543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of hapten-peptide labeling for pretargeted immunoPET of bispecific antibody using generator-produced 68Ga.
    Karacay H; Sharkey RM; McBride WJ; Rossi EA; Chang CH; Goldenberg DM
    J Nucl Med; 2011 Apr; 52(4):555-9. PubMed ID: 21421724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoscintigraphy with positron emission tomography: gallium-68 chelate imaging of breast cancer pretargeted with bispecific anti-MUC1/anti-Ga chelate antibodies.
    Schuhmacher J; Kaul S; Klivényi G; Junkermann H; Magener A; Henze M; Doll J; Haberkorn U; Amelung F; Bastert G
    Cancer Res; 2001 May; 61(9):3712-7. PubMed ID: 11325843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental pretargeting studies of cancer with a humanized anti-CEA x murine anti-[In-DTPA] bispecific antibody construct and a (99m)Tc-/(188)Re-labeled peptide.
    Karacay H; McBride WJ; Griffiths GL; Sharkey RM; Barbet J; Hansen HJ; Goldenberg DM
    Bioconjug Chem; 2000; 11(6):842-54. PubMed ID: 11087333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma.
    Gold DV; Goldenberg DM; Karacay H; Rossi EA; Chang CH; Cardillo TM; McBride WJ; Sharkey RM
    Cancer Res; 2008 Jun; 68(12):4819-26. PubMed ID: 18559529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CEA antibody fragments labeled with [(18)F]AlF for PET imaging of CEA-expressing tumors.
    Lütje S; Franssen GM; Sharkey RM; Laverman P; Rossi EA; Goldenberg DM; Oyen WJ; Boerman OC; McBride WJ
    Bioconjug Chem; 2014 Feb; 25(2):335-41. PubMed ID: 24382090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretargeting of carcinoembryonic antigen-expressing tumors with a biologically produced bispecific anticarcinoembryonic antigen x anti-indium-labeled diethylenetriaminepentaacetic acid antibody.
    van Schaijk FG; Oosterwijk E; Soede AC; Broekema M; Frielink C; McBride WJ; Goldenberg DM; Corstens FH; Boerman OC
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7130s-7136s. PubMed ID: 16203812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Carcinoembryonic-Antigen-(CEA)-Specific Pretargeting System to Assess Tumor Cell Viability after Irradiation of Colorectal Cancer Cells.
    Meller B; Rave-Fränck M; Breunig C; Schirmer M; Baehre M; Nadrowitz R; Liersch T; Meller J
    Strahlenther Onkol; 2011 Feb; 187(2):120-6. PubMed ID: 21271227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging small human prostate cancer xenografts after pretargeting with bispecific bombesin-antibody complexes and targeting with high specific radioactivity labeled polymer-drug conjugates.
    Patil V; Gada K; Panwar R; Varvarigou A; Majewski S; Weisenberger A; Ferris C; Tekabe Y; Khaw BA
    Eur J Nucl Med Mol Imaging; 2012 May; 39(5):824-39. PubMed ID: 22302089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.